Skip to content


Illumina to Offer $650 Million Convertible Senior Notes

SAN DIEGO--(BUSINESS WIRE)--Aug. 15, 2018-- Illumina, Inc. (Nasdaq: ILMN) today announced its intention to offer, subject to market and other conditions, approximately $650 million aggregate principal amount of convertible senior notes due 2023 (the “Notes”). Illumina also intends to grant the initial purchasers a 30-day option to purchase up to an additional $100 million in aggregate principal amount of the Notes, for a total potential offering size of $750 million.

Illumina intends to use the net proceeds of the offering to repurchase up to $150 million of its common stock concurrently with this offering in privately negotiated transactions effected with or through the initial purchasers and/or their affiliates, and Illumina intends to use the remainder of the net proceeds of the offering for general corporate purposes, which may include the repayment of its 0.0% Convertible Senior Notes due 2019.

The Notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and will be convertible under certain circumstances. Upon conversion, holders will receive, at Illumina's election, cash, shares of Illumina's common stock or a combination thereof. The interest rate, conversion rate and other terms of the Notes will be determined by negotiations between Illumina and the initial purchasers of the Notes.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. Any offers of the Notes will be made only by means of a private offering memorandum. The Notes and any shares of Illumina common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Our ability to consummate the offering is subject to market conditions.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services, including expanding manufacturing operations and reliance on third-party suppliers for critical components; (ii) the timing and mix of customer orders among our products and services; (iii) the impact of recently launched or pre-announced products and services on existing products and services; (iv) our ability to further develop and commercialize our instruments and consumables and to deploy new products, services, and applications, and expand the markets, for our technology platforms; (v) our ability to manufacture robust instrumentation and consumables; (vi) the success of products and services competitive with our own; (vii) our ability to successfully identify and integrate acquired technologies, products, or businesses; (viii) our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate; and (ix) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Source: Illumina, Inc.

Illumina, Inc.
Jacquie Ross, CFA
Eric Endicott

Recent Articles

Introducing the Enhanced RNA-Seq Library Prep Product Portfolio
Introducing the Enhanced RNA-Seq Library Prep Product Portfolio
TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assays
TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assays
How Sequencing-Based Surveillance Helps Fight COVID-19
How Sequencing-Based Surveillance Helps Fight COVID-19